Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.53 |
| ▸ | MPO | P05164 | 7/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | REN | P00797 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.42 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethoxycarbonyl Group SCHEMBL27687183 | 0.82 | GPR84 (0.45) | GPR84SLC6A4MPOARHTR2A | |
| SCHEMBL2143637 | 0.80 | TRIM24 (0.60) | ATMARHTR2ARENMAPT | |
| SCHEMBL31049406 | 0.80 | GPR84 (0.64) | GPR84SLC6A4MPORIPK1 | |
| SCHEMBL31607554 | 0.80 | TRIM24 (0.60) | ATMARHTR2ARENMAPT | |
| SCHEMBL15692504 | 0.78 | REN (0.57) | ATMARHTR2ARENMAPT | |
| SCHEMBL16727192 | 0.77 | DYRK1A (0.53) | ATMARHTR2ARENMAPT | |
| SCHEMBL5248011 | 0.77 | ATM (0.48) | ATMHTR2ARENMAPTSMN1; SMN2 | |
| SCHEMBL4078677 | 0.75 | DYRK1A (0.55) | SLC6A4ATMARHTR2AREN | |
| SCHEMBL1137500 | 0.75 | DYRK1A (0.55) | SLC6A4ATMARHTR2AREN | |
| SCHEMBL7089054 | 0.75 | REN (0.50) | ATMHTR2ARENMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3702354-B1 | COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF | HAIHE BIOPHARMA CO LTD (CN) | 2024-05-22 | — | — | EP | disclosed |
| US-20230203018-A1 | COVALENT INHIBITORS OF KRAS | ARAXES PHARMA LLC (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230203018-A1 | COVALENT INHIBITORS OF KRAS | ARAXES PHARMA LLC (US) | 2023-06-29 | — | — | US | disclosed |
| WO-2023018747-A1 | INHIBITORS OF HYPOXIA-INDUCIBLE FACTORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-02-16 | — | — | WO | disclosed |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | disclosed |
| US-11465984-B2 | Compound having ERK kinase inhibitory activity and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2022-10-11 | — | — | US | disclosed |
| WO-2022078416-A1 | NOVEL GLUTAMINE ANALOGS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
| EP-3702354-A1 | COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF | Shanghai Haihe Pharmaceutical Co., Ltd. (CN) | 2020-09-02 | — | — | EP | disclosed |
| EP-3702354-A1 | COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF | Shanghai Haihe Pharmaceutical Co., Ltd. (CN) | 2020-09-02 | — | — | EP | disclosed |
| US-20200247781-A1 | COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF | HAIHE BIOPHARMA CO., LTD. (CN) | 2020-08-06 | — | — | US | disclosed |
| US-20090099164-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
| US-7517899-B2 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2009-04-14 | — | — | US | disclosed |
| US-20090093469-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | WYETH (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2009015067-A2 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-29 | — | — | WO | disclosed |
| WO-2009015067-A2 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-29 | — | — | WO | disclosed |
| WO-2008121670-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008117175-A2 | NOVEL BENZAMIDE DERIVATIVES AS MODULATORS OF THE FOLLICLE STIMULATING HORMONE | ADDEX PHARMA SA (CH) | 2008-10-02 | — | — | WO | disclosed |
| EP-1732887-B1 | 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH CORP (US) | 2008-01-09 | — | — | EP | disclosed |
| CN-1960973-A | 1-(1h-indol-1-yl)-3-(4-methylpiperazin-1-yl)-1-phenyl propan-2-ol derivatives and related compounds as modulators of the norepinephrine(NE) and the serotonine(5-HT) activity and the monoamine reuptake | WYETH CORP (US) | 2007-05-09 | — | — | CN | disclosed |
| US-20050222148-A1 | Phenylaminopropanol derivatives and methods of their use | WYETH (US) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | GPR84 162/4885SLC6A4 1888/4885MPO 538/4885 |
| US-20090099164-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | PAH, PNMT, COMT | GPR84 1874/4885SLC6A4 13/4885MPO 1908/4885 |
| US-11465984-B2 | Compound having ERK kinase inhibitory activity and use thereof | MAPK1, MAPK4, MAPK7 | GPR84 2862/4885SLC6A4 4400/4885MPO 2553/4885 |
| US-20050222148-A1 | Phenylaminopropanol derivatives and methods of their use | PAH, PNMT, COMT | GPR84 1874/4885SLC6A4 13/4885MPO 1908/4885 |
| US-20230203018-A1 | COVALENT INHIBITORS OF KRAS | KRAS, NRAS, HRAS | GPR84 3471/4885SLC6A4 4808/4885MPO 2780/4885 |
| US-20200247781-A1 | COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF | MAPK1, MAPK4, MAPK7 | GPR84 2862/4885SLC6A4 4400/4885MPO 2553/4885 |
| US-20090093469-A1 | Phenylaminopropanol Derivatives and Methods of Their Use | PAH, PNMT, COMT | GPR84 1874/4885SLC6A4 13/4885MPO 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.